What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to officially report Abbott Laboratories' financial results for the first quarter of 2022 and to provide the accompanying press release as an exhibit.

What are non-GAAP financial measures, and why does Abbott use them?

Non-GAAP financial measures are financial metrics that exclude certain items from the standard GAAP (Generally Accepted Accounting Principles) figures. Abbott uses them to adjust for factors they deem unusual or unpredictable, such as acquisition expenses, restructuring costs, and voluntary recalls. The company believes these measures help investors better evaluate the ongoing performance of their business, similar to how management internally assesses performance.

What specific items are excluded in Abbott's non-GAAP measures mentioned in this filing?

The filing mentions exclusions for expenses related to acquisitions, restructuring actions, cost reduction initiatives, a voluntary recall, certain regulatory costs, certain litigation, impairment of certain assets, tax benefits/expenses from specified items, and excess tax benefits from share-based compensation. Intangible amortization expense is also excluded.

Should investors rely solely on the non-GAAP financial measures?

No, Abbott's management cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP. This means investors should review both GAAP and non-GAAP figures for a complete understanding.

ABT 8-K: Earnings & Results

Summary

Abbott Laboratories (ABT) filed an 8-K on April 20, 2022, to report its first quarter 2022 financial results. The filing primarily serves to furnish the press release detailing these results, which was issued on the same day. Investors should note that Abbott utilizes non-GAAP financial measures to provide additional insight into its operational performance. These measures adjust for specific items such as acquisition-related expenses, restructuring costs, voluntary recalls, and amortization of intangibles, aiming to offer a clearer view of ongoing business performance as assessed by management.

Key Highlights

1Abbott Laboratories announced its Q1 2022 financial results on April 20, 2022.
2The 8-K filing includes a press release furnished as an exhibit, detailing the Q1 2022 performance.
3The company employs non-GAAP financial measures in its reporting.
4Non-GAAP measures are adjusted for items like acquisition costs, restructuring, voluntary recalls, and amortization of intangibles.
5Abbott's management believes these non-GAAP measures offer better insight into ongoing business performance.
6Investors are advised to consider non-GAAP measures alongside GAAP financial statements.

ABBOTT LABORATORIES 8-K Report, Financial Results (Apr 20, 2022)

Summary

Key Highlights

Frequently Asked Questions